Novocure Ltd

NVCR

$16.67

Updated: 23/09/2026, 07:06:07

Market Cap

$1.94B

Sector

Healthcare

Industry

Medical - Devices

Country

Stock valuation chart

One-year closing share-price history for NVCR

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

USD

NASDAQ

CEO: Frank Leonard

Employees: 1,605

https://www.novocure.com

Asset Summaries

Latest generated summaries for NVCR

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for NVCR.

Share price: $16.67
Market cap: $1.94B
Exchange: NASDAQ
Currency: USD
CEO: Frank Leonard
Employees: 1,605
IPO date: 02/10/2015
Beta: 1.009
Last dividend: $0.00
Day range: $16.54 – $16.79
52-week range: $9.82 – $21.45
1-day performance: 0.85%
1-year performance: 69.76%
Current drawdown (1Y): -22.29%
CIK: 0001645113
CUSIP: G6674U108
ISIN: JE00BYSS4X48
Created: 07/12/2025, 05:31:48
Last update: 23/09/2026, 07:06:07

Track Novocure Ltd with an AI analyst

See which prediction-market events move NVCR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to NVCR from your Railway `news_articles` table.

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

Seeking Alpha • STOCK • 01/05/2026, 14:35:10

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 30/04/2026, 16:41:46

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Zacks Investment Research • STOCK • 30/04/2026, 11:35:21

NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates

Zacks Investment Research • STOCK • 26/02/2026, 14:21:34

NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 26/02/2026, 12:17:50

Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer

Zacks Investment Research • STOCK • 17/02/2026, 12:05:24